Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873919 | 0.85 | PDE2A (0.45) | F10 | |
| SCHEMBL8346292 | 0.85 | F10 (0.43) | F10KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8347891 | 0.84 | L3MBTL1 (0.47) | F10MEN1MAPTKMT2AHSD17B10 | |
| SCHEMBL8344662 | 0.82 | KDM4E (0.40) | F10KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3863014 | 0.81 | CSNK2A2 (0.49) | F10KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL8346713 | 0.80 | F10 (0.47) | F10KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL13759438 | 0.80 | F10 (0.43) | F10 | |
| SCHEMBL12922914 | 0.79 | F10 (0.47) | F10MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3865007 | 0.79 | F10 (0.40) | F10KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3865284 | 0.79 | CHEK2 (0.54) | HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566789-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-7566789-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-7566789-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| EP-1558247-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-20 | — | — | EP | disclosed |
| EP-1558247-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-20 | — | — | EP | disclosed |
| US-20050272740-A1 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| CN-1674893-A | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1558247-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004017963-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272740-A1 | Benzimidazole derivatives | F12, F11, SERPINC1 | F10 5/4885KDM4E 1595/4885MEN1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.